Education
About Us
Working with TipRanks
Follow Us
Viridian Therapeutics (VRDN)
NASDAQ:VRDN
VRDN Stock Chart & Stats
$24.21
-$0.90(-4.30%)
At close: 4:00 PM EST
$24.21
-$0.90(-4.30%)
Day’s Range― - ―
52-Week Range$9.90 - $27.20
Previous CloseN/A
Volume201.32K
Average Volume (3M)804.08K
Market Cap
$1.98B
Enterprise Value$789.25M
Total Cash (Recent Filing)$563.36M
Total Debt (Recent Filing)$21.34M
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Nov 18, 2025EPS Estimate
-0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding81,662,370
10 Day Avg. Volume1,048,827
30 Day Avg. Volume804,081
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue2.59K
Enterprise Value/Gross Profit4.34K
Enterprise Value/Ebitda-2.32
Forecast
1Y Price Target
$39.73Price Target Upside64.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst recommendation for Viridian is 'OUTPERFORM', suggesting confidence in the company's performance.
Pipeline ProgressViridian recently completed enrollment of the REVEAL program, which is evaluating VRDN-003 in both active and chronic Thyroid Eye Disease.
Product DesignationVeligrotug has been granted Breakthrough Therapy Designation, indicating its potential as a valuable treatment option.
Therapy EfficacyVRDN's Veligrotug demonstrated a significantly higher proptosis response rate compared to Roche's Satralizumab, positioning it as a more effective treatment for TED.
Bears Say
CompetitionRoche's Satralizumab showed underwhelming results in clinical trials, reducing its competitive threat to VRDN.
Market CompetitionThe trial failure likely ends another TED development program and potential competitor to VRDN's veligrotug and VRDN-003.
Viridian Therapeutics News
VRDN FAQ
What was Viridian Therapeutics’s price range in the past 12 months?
Viridian Therapeutics lowest stock price was $9.90 and its highest was $27.20 in the past 12 months.
What is Viridian Therapeutics’s market cap?
Viridian Therapeutics’s market cap is $1.98B.
When is Viridian Therapeutics’s upcoming earnings report date?
Viridian Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 28 days.
How were Viridian Therapeutics’s earnings last quarter?
Viridian Therapeutics released its earnings results on Aug 06, 2025. The company reported -$1 earnings per share for the quarter, beating the consensus estimate of -$1.009 by $0.009.
Is Viridian Therapeutics overvalued?
According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued.
Does Viridian Therapeutics pay dividends?
Viridian Therapeutics does not currently pay dividends.
What is Viridian Therapeutics’s EPS estimate?
Viridian Therapeutics’s EPS estimate is -0.95.
How many shares outstanding does Viridian Therapeutics have?
Viridian Therapeutics has 81,662,370 shares outstanding.
What happened to Viridian Therapeutics’s price movement after its last earnings report?
Viridian Therapeutics reported an EPS of -$1 in its last earnings report, beating expectations of -$1.009. Following the earnings report the stock price went down -1.376%.
Which hedge fund is a major shareholder of Viridian Therapeutics?
Currently, no hedge funds are holding shares in VRDN
Viridian Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.73 (64.11% Upside)
$39.73 (64.11% Upside)
Blogger Sentiment
Bullish
VRDN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 859.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.20%
12-Months-Change
Fundamentals
Return on Equity
-62.99%
Trailing 12-Months
Asset Growth
-0.57%
Trailing 12-Months
Company Description
Viridian Therapeutics
Viridian Therapeutics, Inc. (VRDN) is a biotechnology company focused on developing innovative therapies for patients with serious diseases, particularly in the field of ophthalmology and autoimmune disorders. The company leverages its proprietary technology platforms to design and produce monoclonal antibodies and other biologics that address unmet medical needs. With a commitment to advancing the science of therapeutic development, Viridian aims to deliver transformative treatments to improve patient outcomes.
VRDN Stock 12 Month Forecast
Average Price Target
$39.73
▲(64.11% Upside)
Technical Analysis
Dianthus Therapeutics
―
Pharvaris
―
Edgewise Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
4.27% Insiders
28.06% Mutual Funds
1.28% Other Institutional Investors
53.46% Public Companies and
Individual Investors